These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32392114)

  • 1. Hepatitis C Virus Infection and Treatment as Independent Prognostic Factors in Diffuse Large B-Cell Lymphoma Egyptian Patients.
    Elbedewy TA; Elashtokhy HEA; Abd-Elsalam S; Suliman MA
    Curr Cancer Drug Targets; 2020; 20(8):638-645. PubMed ID: 32392114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients.
    Hosry J; Miranda RN; Samaniego F; Economides MP; Torres HA
    Int J Cancer; 2018 Mar; 142(5):940-948. PubMed ID: 29047108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index.
    Chen YY; Huang CE; Liang FW; Lu CH; Chen PT; Lee KD; Chen CC
    Cancer Epidemiol; 2015 Jun; 39(3):382-7. PubMed ID: 25899771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era.
    Zaky AH; Bakry R; El-sayed MI; Elwanis MA; Nabih O
    Hematology; 2014 Oct; 19(7):412-6. PubMed ID: 24620947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis.
    Ennishi D; Maeda Y; Niitsu N; Kojima M; Izutsu K; Takizawa J; Kusumoto S; Okamoto M; Yokoyama M; Takamatsu Y; Sunami K; Miyata A; Murayama K; Sakai A; Matsumoto M; Shinagawa K; Takaki A; Matsuo K; Kinoshita T; Tanimoto M
    Blood; 2010 Dec; 116(24):5119-25. PubMed ID: 20823454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Dlouhy I; Torrente MÁ; Lens S; Rovira J; Magnano L; Giné E; Delgado J; Balagué O; Martínez A; Campo E; Forns X; Sánchez-Tapias JM; López-Guillermo A
    Ann Hematol; 2017 Mar; 96(3):405-410. PubMed ID: 28035434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment.
    Visco C; Finotto S
    World J Gastroenterol; 2014 Aug; 20(32):11054-61. PubMed ID: 25170194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma.
    Persico M; Aglitti A; Caruso R; De Renzo A; Selleri C; Califano C; Abenavoli L; Federico A; Masarone M
    Hepatology; 2018 Jan; 67(1):48-55. PubMed ID: 28714143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma.
    Hosry J; Mahale P; Turturro F; Miranda RN; Economides MP; Granwehr BP; Torres HA
    Int J Cancer; 2016 Dec; 139(11):2519-28. PubMed ID: 27501007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs.
    Besson C; Canioni D; Lepage E; Pol S; Morel P; Lederlin P; Van Hoof A; Tilly H; Gaulard P; Coiffier B; Gisselbrecht C; Brousse N; Reyes F; Hermine O;
    J Clin Oncol; 2006 Feb; 24(6):953-60. PubMed ID: 16418500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience.
    Nishikawa H; Tsudo M; Osaki Y
    Oncol Rep; 2012 Sep; 28(3):835-40. PubMed ID: 22736295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.
    Cheng CL; Huang SC; Chen JH; Wei CH; Fang WQ; Su TH; Yuan CT; Liu JH; Chuang MK; Tien HF
    Oncologist; 2020 Sep; 25(9):793-802. PubMed ID: 32275807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi.
    Merli M; Visco C; Spina M; Luminari S; Ferretti VV; Gotti M; Rattotti S; Fiaccadori V; Rusconi C; Targhetta C; Stelitano C; Levis A; Ambrosetti A; Rossi D; Rigacci L; D'Arco AM; Musto P; Chiappella A; Baldini L; Bonfichi M; Arcaini L
    Haematologica; 2014 Mar; 99(3):489-96. PubMed ID: 24270404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus seroprevalence in patients with diffuse large B cell lymphoma and Hodgkin's lymphoma.
    Mert D; Merdin A; Ceken S; Dal MS; Ertek M; Altuntas F
    J Cancer Res Ther; 2021; 17(4):951-955. PubMed ID: 34528547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the presence of hepatitis virus B and C influence the evolution of diffuse large B-cell lymphoma?
    Rubio J; Franco F; Sánchez A; Cantos B; Méndez M; Calvo V; Maximiano C; Perez D; Millán I; Sánchez-Beato M; Provencio M
    Leuk Lymphoma; 2015 Jun; 56(6):1686-90. PubMed ID: 25219591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C infection is associated with hepatic toxicity but does not compromise the survival of patients with diffuse large B cell lymphoma treated with rituximab-based chemotherapy.
    Chen TT; Chiu CF; Yang TY; Lin CC; Sargeant AM; Yeh SP; Liao YM; Bai LY
    Leuk Res; 2015 Feb; 39(2):151-6. PubMed ID: 25524176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study.
    Michot JM; Canioni D; Driss H; Alric L; Cacoub P; Suarez F; Sibon D; Thieblemont C; Dupuis J; Terrier B; Feray C; Tilly H; Pol S; Leblond V; Settegrana C; Rabiega P; Barthe Y; Hendel-Chavez H; Nguyen-Khac F; Merle-Béral H; Berger F; Molina T; Charlotte F; Carrat F; Davi F; Hermine O; Besson C;
    Am J Hematol; 2015 Mar; 90(3):197-203. PubMed ID: 25417909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma.
    Tsutsumi Y; Nakayama C; Kamada K; Kikuchi R; Kudo D; Ito S; Matsuoka S; Shiratori S; Yamamoto Y; Naruse H; Teshima T
    Ann Hematol; 2017 Dec; 96(12):2057-2061. PubMed ID: 28939993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma.
    Zhou X; Wuchter P; Egerer G; Kriegsmann M; Mataityte A; Koelsche C; Witzens-Harig M; Kriegsmann K
    Eur J Haematol; 2019 Oct; 103(4):410-416. PubMed ID: 31338887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.